It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
CADM2 has been associated with a range of behavioural and metabolic traits, including physical activity, risk-taking, educational attainment, alcohol and cannabis use and obesity. Here, we set out to determine whether CADM2 contributes to mechanisms shared between mental and physical health disorders. We assessed genetic variants in the CADM2 locus for association with phenotypes in the UK Biobank, IMPROVE, PROCARDIS and SCARFSHEEP studies, before performing meta-analyses. A wide range of metabolic phenotypes were meta-analysed. Psychological phenotypes analysed in UK Biobank only were major depressive disorder, generalised anxiety disorder, bipolar disorder, neuroticism, mood instability and risk-taking behaviour. In UK Biobank, four, 88 and 172 genetic variants were significantly (p < 1 × 10−5) associated with neuroticism, mood instability and risk-taking respectively. In meta-analyses of 4 cohorts, we identified 362, 63 and 11 genetic variants significantly (p < 1 × 10−5) associated with BMI, SBP and CRP respectively. Genetic effects on BMI, CRP and risk-taking were all positively correlated, and were consistently inversely correlated with genetic effects on SBP, mood instability and neuroticism. Conditional analyses suggested an overlap in the signals for physical and psychological traits. Many significant variants had genotype-specific effects on CADM2 expression levels in adult brain and adipose tissues. CADM2 variants influence a wide range of both psychological and metabolic traits, suggesting common biological mechanisms across phenotypes via regulation of CADM2 expression levels in adipose tissue. Functional studies of CADM2 are required to fully understand mechanisms connecting mental and physical health conditions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 University of Glasgow, Institute of Health and Wellbeing, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X)
2 University of Glasgow, School of Life Sciences, College of Medical, Veterinary and Life Sciences, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X)
3 Università degli Studi di Milano, Department of Medical Biotechnology and Translational Medicine, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822); Centro Cardiologico Monzino, IRCCS, Milan, Italy (GRID:grid.418230.c) (ISNI:0000 0004 1760 1750)
4 Institute of Environmental Medicine, Karolinska Institutet, Unit of Cardiovascular Epidemiology, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
5 Institute of Environmental Medicine, Karolinska Institutet, Unit of Cardiovascular Epidemiology, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Danderyd University Hospital, Division of Cardiovascular Medicine, Department of Clinical Sciences, Stockholm, Sweden (GRID:grid.412154.7) (ISNI:0000 0004 0636 5158)
6 Groupe Hôpitalier Pitie-Salpetriere, Unités de Prévention Cardiovasculaire, Assistance Publique-Hopitaux de Paris, Service Endocrinologie-Metabolisme, Paris, France (GRID:grid.412154.7)
7 Radcliffe Department of Medicine, University of Oxford, Division of Cardiovascular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Wellcome Centre for Human Genetics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
8 Karolinska Institutet, Cardiovascular Medicine Unit, Department of Medicine Solna, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
9 University College London, Centre for Cardiovascular Genetics, Institute Cardiovascular Science, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
10 University of Glasgow, Institute of Health and Wellbeing, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X); University of Glasgow, School of Life Sciences, College of Medical, Veterinary and Life Sciences, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X); University of Edinburgh, Division of Psychiatry, College of Medicine, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
11 Uppsala University, Department of Cell and Molecular Biology, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457)
12 University Medical Center Groningen and University of Groningen, Department of Medicine, Groningen, The Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598)
13 Centro Cardiologico Monzino, IRCCS, Milan, Italy (GRID:grid.418230.c) (ISNI:0000 0004 1760 1750); Università di Milano, Dipartimento di Scienze Farmacologiche e Biomolecolari, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822)
14 Centro Cardiologico Monzino, IRCCS, Milan, Italy (GRID:grid.418230.c) (ISNI:0000 0004 1760 1750)
15 University of Glasgow, Institute of Health and Wellbeing, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X); Karolinska Institutet, Cardiovascular Medicine Unit, Department of Medicine Solna, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)